Oppenheimer Issues Positive Forecast for Gilead Sciences (NASDAQ:GILD) Stock Price

Gilead Sciences (NASDAQ:GILD) had its target price upped by Oppenheimer from $105.00 to $115.00 in a research report sent to investors on Tuesday,Benzinga reports. They currently have an outperform rating on the biopharmaceutical company’s stock.

GILD has been the topic of a number of other reports. Barclays raised their target price on Gilead Sciences from $84.00 to $95.00 and gave the company an “equal weight” rating in a research note on Thursday, November 7th. Daiwa America upgraded shares of Gilead Sciences to a “hold” rating in a research report on Monday, November 18th. Mizuho upped their target price on shares of Gilead Sciences from $90.00 to $100.00 and gave the stock an “outperform” rating in a research report on Thursday, November 21st. Bank of America reaffirmed a “buy” rating and set a $109.00 price target on shares of Gilead Sciences in a report on Tuesday. Finally, Cantor Fitzgerald increased their price objective on Gilead Sciences from $70.00 to $80.00 and gave the stock a “neutral” rating in a report on Thursday, November 7th. Twelve research analysts have rated the stock with a hold rating, twelve have issued a buy rating and four have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $96.43.

Gilead Sciences Trading Up 1.9 %

NASDAQ GILD opened at $92.34 on Tuesday. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.10 and a current ratio of 1.26. Gilead Sciences has a one year low of $62.07 and a one year high of $98.90. The company has a 50-day simple moving average of $89.33 and a 200-day simple moving average of $78.89. The firm has a market capitalization of $115.08 billion, a PE ratio of 1,026.00, a price-to-earnings-growth ratio of 2.86 and a beta of 0.18.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 EPS for the quarter, beating analysts’ consensus estimates of $1.58 by $0.44. The company had revenue of $7.55 billion during the quarter, compared to the consensus estimate of $7.01 billion. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. Gilead Sciences’s quarterly revenue was up 7.0% compared to the same quarter last year. During the same period in the previous year, the firm posted $2.29 earnings per share. On average, equities analysts forecast that Gilead Sciences will post 4.37 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 30th. Stockholders of record on Friday, December 13th will be given a dividend of $0.77 per share. The ex-dividend date is Friday, December 13th. This represents a $3.08 dividend on an annualized basis and a dividend yield of 3.34%. Gilead Sciences’s dividend payout ratio (DPR) is presently 3,422.22%.

Insider Transactions at Gilead Sciences

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 248,645 shares of the firm’s stock in a transaction dated Friday, November 29th. The shares were sold at an average price of $92.76, for a total value of $23,064,310.20. Following the completion of the transaction, the chief financial officer now directly owns 138,919 shares in the company, valued at $12,886,126.44. This trade represents a 64.16 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, insider Merdad Parsey sold 2,000 shares of Gilead Sciences stock in a transaction that occurred on Tuesday, October 1st. The stock was sold at an average price of $83.83, for a total transaction of $167,660.00. Following the completion of the transaction, the insider now directly owns 100,189 shares in the company, valued at approximately $8,398,843.87. This trade represents a 1.96 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 476,591 shares of company stock valued at $43,747,615 in the last three months. 0.29% of the stock is currently owned by corporate insiders.

Institutional Trading of Gilead Sciences

A number of hedge funds have recently modified their holdings of the business. Garden State Investment Advisory Services LLC acquired a new position in Gilead Sciences during the third quarter valued at $221,000. Franklin Resources Inc. increased its holdings in shares of Gilead Sciences by 22.8% in the 3rd quarter. Franklin Resources Inc. now owns 2,241,354 shares of the biopharmaceutical company’s stock valued at $190,611,000 after purchasing an additional 416,379 shares during the period. Tri Ri Asset Management Corp purchased a new stake in shares of Gilead Sciences in the third quarter worth approximately $3,380,000. Synovus Financial Corp boosted its holdings in shares of Gilead Sciences by 99.6% during the third quarter. Synovus Financial Corp now owns 37,265 shares of the biopharmaceutical company’s stock worth $3,124,000 after purchasing an additional 18,592 shares during the period. Finally, Tidal Investments LLC grew its position in Gilead Sciences by 9.9% during the third quarter. Tidal Investments LLC now owns 111,464 shares of the biopharmaceutical company’s stock valued at $9,345,000 after purchasing an additional 10,078 shares in the last quarter. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.